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No treatment for frontotemporal dementia (FTD), the second most common type of early-onset dementia, is available,
but therapeutics are being investigated to target the 2 main proteins associated with FTD pathological subtypes: TDP-43
(FTLD-TDP) and tau (FTLD-tau). Testing potential therapies in clinical trials is hampered by our inability to distinguish
between patients with FTLD-TDP and FTLD-tau. Therefore, we evaluated truncated stathmin-2 (STMN2) as a proxy of
TDP-43 pathology, given the reports that TDP-43 dysfunction causes truncated STMN2 accumulation. Truncated STMN2
accumulated in human induced pluripotent stem cell–derived neurons depleted of TDP-43, but not in those with pathogenic
TARDBP mutations in the absence of TDP-43 aggregation or loss of nuclear protein. In RNA-Seq analyses of human brain
samples from the NYGC ALS cohort, truncated STMN2 RNA was confined to tissues and disease subtypes marked by TDP43 inclusions. Last, we validated that truncated STMN2 RNA was elevated in the frontal cortex of a cohort of patients with
FTLD-TDP but not in controls or patients with progressive supranuclear palsy, a type of FTLD-tau. Further, in patients with
FTLD-TDP, we observed significant associations of truncated STMN2 RNA with phosphorylated TDP-43 levels and an earlier
age of disease onset. Overall, our data uncovered truncated STMN2 as a marker for TDP-43 dysfunction in FTD.

Introduction

Tar DNA-binding protein 43 (TDP-43) regulates multiple aspects
of RNA metabolism, including RNA stabilization, transcription,
splicing, and transport (1). TDP-43 binds thousands of RNAs (2,
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3) and, for particular genes, represses nonconserved cryptic exons
in a species- (4) and cell-type–specific manner (5, 6). Recently,
2 groups independently found that TDP-43 is required for the
correct splicing and expression of stathmin-2 (STMN2) (7, 8), a
microtubule-associated protein involved in axonal regeneration
(9). As shown schematically in Figure 1, when TDP-43 is present
and functional, it binds to GU-rich sequences in the first intron
of the STMN2 transcript, allowing normal splicing of intron 1 and
repressing the usage of an alternative or cryptic polyadenylation
site. Reduced TDP-43 binding to STMN2 pre-mRNA, which could
occur as a result of TDP-43 nuclear depletion, leads to the inclusion of a region within intron 1 (exon 2a) and introduces a premature stop codon and polyadenylation. This causes the accumulation of a truncated variant of STMN2 that lacks exons 2 through 5.
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Figure 1. Truncated STMN2 RNA is generated with loss of nuclear TDP-43. Schematic of TDP-43–regulated STMN2 splicing. When TDP-43 is present and
functional, it binds to GU-rich sequences in the first intron of the STMN2 transcript and allows normal splicing of intron 1. Reduced TDP-43 binding to STMN2
RNA, from TDP-43 aggregation or depletion from the nucleus, leads to mis-splicing of STMN2 RNA, resulting in the inclusion of a novel exon encoded within
intron 1 (termed exon 2a) and containing an alternative or cryptic polyadenylation site. The production of this alternative variant of STMN2, which lacks exons
2 through 5 (referred to as truncated STMN2), is at the expense of full-length STMN2, which is reduced upon TDP-43 downregulation.

Neuronal and glial inclusions of TDP-43 are a pathological hallmark of the majority (~97%) of patients with ALS and
of approximately 50% of cases with the pathological subtype
of frontotemporal dementia (FTD), known as frontotemporal lobar degeneration–TDP (FTLD-TDP) (1). ALS is a motor
neuron disease (MND), whereas patients with FTD present
clinically with 1 or more of the FTD syndromes characterized
by behavior, executive function, language, and motor impairments (10). TDP-43 abnormalities are proposed to play a direct
role in these diseases, since mutations in TARDBP, the gene
that encodes TDP-43, were discovered in sporadic and familial
ALS and FTD (11, 12). It is also notable that TDP-43 morphology and distribution are associated with clinical phenotypes and
neurodegeneration in key anatomical regions, such as frontal
and temporal cortices in FTLD-TDP (13). Cells with TDP-43
pathology feature a redistribution of TDP-43 from the nucleus to the cytoplasm, where TDP-43 is ubiquitinated, hyperphosphorylated, and cleaved into C-terminal fragments (14).
Patients with FTLD-TDP can be further classified into different pathological subtypes on the basis of the morphology and
distribution of the TDP-43 inclusions observed (15, 16). These
can take the form of neuronal cytoplasmic inclusions, dystrophic neurites, neuronal intranuclear inclusions, glial inclusions,
perivascular inclusions, and fine neurites in the hippocampus
(14, 17–20). At present, 5 subtypes of FTLD-TDP (A–E) have
been identified (15, 20–23), with types A–C accounting for more
than 95% of all FTLD-TDP cases (24). FTLD-TDP type A, the
most common subtype, is characterized by the presence of all
the inclusion types mentioned above, whereas types B–E are
characterized by the presence of a predominant inclusion type
(19, 22). Furthermore, some FTLD-TDP subtypes are associated with particular mutations (20, 25, 26).

While approximately 50% of patients with an FTD syndrome
have underlying TDP-43 pathology, such pathology can, at present, only be definitively confirmed at autopsy. Given the efforts to
develop therapies specific to FTLD pathological subtypes (i.e., FTD
with TDP-43 vs. tau pathology), there is a clear need for biomarkers
that discriminate between them. Further, biomarkers for diagnosis or prognosis or that can monitor TDP-43 activity in response to
TDP-43–tailored therapies are also sorely lacking. Although TDP-43
represents an attractive biomarker candidate to fulfill these needs,
efforts to develop sufficiently sensitive immunoassays for the detection of TDP-43 or its pathological forms in biofluids and that reliably
differentiate between individuals with and without TDP-43 pathology have proven disappointing (27). However, nuclear clearance of
TDP-43, in the absence of TDP-43 inclusions, has been associated
with neuronal atrophy in patients with FTLD-TDP or ALS-TDP (28),
suggesting that early mis-splicing events due to TDP-43 loss of function may represent a robust and early disease biomarker.
We thus propose that the mis-splicing of STMN2 may provide
a novel strategy for the indirect assessment of TDP-43 dysfunction. To test this hypothesis, we first validated the STMN2 splicing event in induced pluripotent stem cell–derived (iPSC-derived)
cortical and motor neurons that were TDP-43 depleted. Then,
we evaluated whether the truncated STMN2 isoform accumulates in diseases and tissues characterized by TDP-43 pathology
using data sets from RNA-Seq studies of brain tissues from a large
cohort of control subjects and of patients with FTD or ALS with or
without TDP-43 pathology. Furthermore, we measured truncated
and full-length STMN2 RNA levels in postmortem medial frontal
cortex tissue from FTLD-TDP, progressive nuclear palsy (PSP),
and pathologically normal control brains. PSP was selected as the
disease control, given that TDP-43 pathology is not found in the
frontal cortex of these patients with FTLD-tau (29). We additionjci.org   Volume 130   Number 11   November 2020
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ally evaluated whether truncated STMN2 levels in the medial frontal cortex discriminated between patients with FTLD-TDP and
control subjects and assessed associations of truncated SMTN2
with phosphorylated TDP-43 (p–TDP-43) and clinical features.

Results

TDP-43 depletion in human iPSC–derived neurons leads to aberrant
STMN2 splicing. To confirm recent reports that correct STMN2 splicing requires TDP-43 (7, 8), we used clustered regularly interspaced
short palindromic repeat inactivation (CRISPRi) to knock down TDP43 expression in human iPSC–derived cortical neurons that constitutively express nuclease deactivated Cas9 (dCas9) fused to blue
fluorescent protein (BFP) and the transcriptional repressor Krüppel-associated box (KRAB) (dCas9-BFP-KRAB) (30). To achieve this,
cells were transduced with a lentivirus expressing either an sgRNA
against the transcriptional start site of TARDBP (TDP-43 KD), or a
control sgRNA predicted not to bind anywhere in the human genome
(controls). We confirmed silencing of TARDBP RNA by quantitative
reverse transcription PCR (qRT-PCR) and RNA-Seq (data set labeled
“a”), which showed TDP-43–KD efficiencies of approximately 50%
(47.4% for qRT-PCR, 63.9% for RNA-Seq) (Figure 2A). Reduced
TARDBP levels resulted in significant reductions of full-length
STMN2 RNA (56.7% for qRT-PCR, 65.5% for RNA-Seq) (Figure 2B)
and a significant increase in truncated STMN2 RNA (qRT-PCR, 32.3fold increase) (Figure 2C) and RNA-Seq (Figure 2D, data set labeled
“a”) compared with levels in neurons expressing control sgRNA. In
parallel, we analyzed published RNA-Seq data from Klim et al. on
iPSC-derived motor neurons in which TARDBP was knocked down
(7). Knockdown of TARDBP (Supplemental Figure 1A; supplemental
material available online with this article; https://doi.org/10.1172/
JCI139741DS1) was confirmed in the Klim data set (data set labeled
“b”) and, as expected, was accompanied by a reduction in full-length
STMN2 RNA levels (Supplemental Figure 1B) and an increase in truncated STMN2 RNA levels (Figure 2D, data set labeled “b”).
We also investigated whether disease-causing mutations of
TARDBP, in the absence of TDP-43 protein mislocalization or a
reduction of nuclear levels, are sufficient to impact STMN2 splicing. We evaluated truncated STMN2 expression in RNA-Seq data
from 2 independent studies that used iPSC-derived motor neurons from patients carrying ALS pathogenic TARDBP mutations
and from control subjects (Supplemental Table 1). In contrast to
neurons in which TARDBP was downregulated, we observed no
increase in truncated STMN2 in motor neurons with TARDBP
mutations (Figure 2D, data sets labeled “c” and “d”). This observation was consistent with the lack of change in TDP-43 localization (Figure 2E), TARDBP RNA levels (Supplemental Figure 2), and
TDP-43 protein levels (Supplemental Figure 3) in TARDBP-mutant
motor neurons. Overall, these data suggest that truncated STMN2
accumulation in iPSC-derived neurons results from a loss of TDP43 function due to TDP-43 depletion and not from splicing function
changes arising from mutations in TARDBP (31). The redistribution
of TDP-43 from the nucleus and its sequestration into cytoplasmic
inclusions, a pathological hallmark of FTD and ALS, with and without a genetic link to TARDBP, are consistent with loss-of-function
mechanisms that would lead to STMN2 mis-splicing and an upregulation of truncated STMN2 expression and prompted us to further
examine this in human tissue from FTD and ALS patients.
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Analyses of bulk brain tissue RNA-Seq data uncover tissue-specific truncated STMN2 RNA accumulation in diseases characterized
by TDP-43 pathology. We quantified the expression of full-length
and truncated STMN2 in the NYGC ALS Consortium RNA-Seq
data set across multiple neuroanatomical regions and diseases.
As of March 2020, we were able to examine 11 tissues, with 1659
RNA-Seq samples from 439 donors matching established criteria
for inclusion (see Methods). Donors were diagnosed as non-neurological disease controls or as having FTD, ALS, FTD with ALS
(ALS-FTLD), or ALS with suspected Alzheimer’s disease (ALSAD). Patients with FTD were classified on the basis of their neuropathological diagnosis: FTLD-TDP, FTLD-tau, or FTLD with
mutations in FUS (FTLD-FUS). ALS samples were divided into
those with a SOD1 mutation (ALS-SOD1) versus those without
a SOD1 mutation and thus assumed to have TDP-43 pathology (ALS-TDP). However, pathology confirming the presence of
TDP-43 mislocalization in patients with ALS-TDP was not systematically reported (see Methods).
For each sample, we estimated the expression of full-length
STMN2 using all RNA-Seq reads covering known STMN2 exons,
whereas the truncated STMN2 isoform was quantified using
high-confidence spliced RNA-Seq reads that unambiguously
connected STMN2 exon 1 with the cryptic exon 2a (exon 1–exon
2a) (Figure 3A). We found that full-length STMN2 was highly
expressed in both cortical and cerebellar tissues (median transcripts per million [TPM] in frontal cortex = 58.0 and in cerebellum = 73.1) compared with expression levels in spinal cord
(median TPM in lumbar spinal cord = 6.7), presumably because its
expression is restricted to neurons and because of the higher white
matter composition in the spinal cord (Supplemental Figure 4).
We then estimated the expression of truncated STMN2 in the
NYGC ALS cohort in disease groups across tissues. At least 2 reads
spanning the exon 1–exon 2a junction could be detected in 398 of
the 1659 samples in the data set (24.0%) (Supplemental Figure 5).
Samples that expressed the splice junction did so at a median read
count of 6 (0.13 reads per million) and a maximum read count of
120 (2.5 reads per million) (Supplemental Figure 6). We therefore
chose to model truncated STMN2 expression as a binary outcome,
with a detection threshold of 2 junction reads uniquely mapped
across the intron boundary.
Truncated STMN2 was present in disease subtypes known to
have TDP-43 pathology, as it was detected in the frontal cortex of
82.4% of patients with FTLD-TDP but was absent in those with
FTLD-FUS or FTLD-tau and in controls (Figure 3B). In ALS lumbar spinal cord, we detected truncated STMN2 in 62.2% of patients
with ALS with presumed TDP-43 pathology (ALS-TDP) but not in
patients with ALS-SOD1 or in control individuals (Figure 3C).
We observed an exquisite specificity of truncated STMN2
expression in tissues known to have TDP-43 pathology. In patients
with FTLD-TDP, for whom frontal cortex, temporal cortex, and
cerebellum data sets were available, we detected truncated STMN2
in frontal and temporal cortices but not in cerebellum (Figure 3D).
In ALS-TDP tissues, which also included hippocampus, temporal
cortex, motor cortex, occipital cortex, and spinal cord samples,
truncated STMN2 expression was most prevalent in the spinal
cord, followed by the motor cortex and frontal cortex, with little
to no expression detected in the occipital cortex or cerebellum,
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Figure 2. Truncated STMN2 RNA is elevated in iPSC-derived neurons with reduced levels of TDP-43. (A–C) iPSC-derived cortical neurons constitutively expressing CRISPR inactivation machinery (data set labeled “a”) were transduced with a lentivirus expressing a sgRNA against TARDBP (TDP-43 KD) or a control sgRNA
(Controls) and subjected to analysis by qRT-PCR (n = 3 TDP-43 KD, n = 3 controls) and/or RNA-Seq (n = 3 TDP-43 KD, n = 4 controls). The graphs show a decrease
in TARDBP transcripts (A), a reduction of the full-length STMN2 transcript (B), and an increase in the truncated STMN2 transcript (C) upon TDP-43 depletion. (D)
Detection of STMN2 cryptic exon 2a inclusion expressed as PSI by RNA-Seq in various iPSC-derived neurons: iPSC-derived cortical neurons (data set labeled “a”)
described above and performed in this study; iPSC-derived motor neurons treated with TARDBP siRNA (TDP-43 KD) or control siRNA (controls) from Klim et al.
(data set labeled “b”) (n = 6 TDP-43 KD, n = 11 controls) (7); iPSC-derived motor neurons from patients with TARDBP mutations (TDP-43 mut.) or controls from 2
independent groups in Edinburgh (data set labeled “c”) (n = 7 TDP-43 KD, n = 4 controls) and Oxford (data set labeled “d”) (n = 10 TDP-43 KD, n = 4 controls) (72).
Data are presented as the mean ± SEM and were normalized to the control groups in A and B (set to 100%). *P < 0.05, ***P < 0.005, and ****P < 0.001, by Student’s t test (A–C) or 1-way ANOVA (D). (E) Representative images of iPSC-derived motor neurons from patients with TARDBP mutations and control subjects
from a group in Oxford (data set labeled “d” in Figure 1D) showed similar nuclear-cytoplasmic distribution of TDP-43 (green) on day 30 of differentiation (DAPI
in blue, choline acetyltransferase [ChAT] in white). Scale bar: 10 μm. All panels of Figure 2E are reshown in Supplemental Figure 3A. Additional data associated
with this figure can also be found in Supplemental Figure 3. See also the complete unedited blots in the supplemental material.

respectively (Figure 3E and Supplemental Figure 5). As anticipated,
patients with concurrent FTD and ALS (ALS-FTLD) had truncated STMN2 expression in frontal and temporal cortices, as well as
in the motor cortex and spinal cord (Supplemental Figure 7A). In
contrast, patients with ALS-AD strongly resembled patients with
ALS-TDP in their truncated STMN2 detection patterns, with most
truncated STMN2 expression found in spinal cord and reduced or
no expression in cortical brain regions (Supplemental Figure 7B).
Together, these findings demonstrate that truncated STMN2 RNA
is detected in diseases and tissues characterized by TDP-43 pathology, supporting its potential as a marker for TDP-43 dysfunction.

Truncated STMN2 RNA expression is elevated in FTLD-TDP frontal cortex. Given that we detected truncated STMN2 RNA in patients
with FTLD-TDP but not in those with FTLD-FUS or FTLD-tau (Figure 3B), this aberrant splicing event may provide a means to identify patients with FTD with marked TDP-43 pathology. To further
examine the relationship between TDP-43 and STMN2 in patients
with FTD, we used the NanoString PlexSet platform to systematically quantify truncated and full-length STMN2 RNA levels in frontal cortex tissue from a cohort of 238 patients with FTD with immunohistologically confirmed TDP-43–immunoreactive inclusions, a
cohort of 33 cognitively normal controls who were TDP-43 negative
jci.org   Volume 130   Number 11   November 2020
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Figure 3. Truncated STMN2 RNA is detected in bulk RNA-Seq from FTLD/ALS tissues with TDP-43 pathology. (A) The NYGC ALS Consortium RNA-Seq
data set was analyzed for the presence of truncated STMN2 transcripts, which were identified by RNA-Seq reads spanning the exon 1–exon 2a splice
junction. (B–E) Bar graphs represent the proportion of individuals (percentage) with at least 2 reads spanning the exon 1–exon 2a junction. The number of
individuals for the samples of the indicated tissues/diseases is indicated. (B) Truncated STMN2 was detected in the frontal cortex of patients with FTLDTDP but not in control subjects or patients with FTLD-FUS or FTLD-tau. (C) In the lumbar spinal cord of patients with ALS, truncated STMN2 RNA was only
detected in ALS-TDP samples but not in ALS-SOD1 or control samples. (D) Among FTLD-TDP tissues, truncated STMN2 was only detected in those known
to have TDP-43 pathology (frontal and temporal cortex), whereas (E) within ALS-TDP tissues, truncated STMN2 RNA was seen in motor cortex and spinal
cord tissues but not in regions without TDP-43 pathology.

(henceforth referred to as controls), and a cohort of 41 patients with
PSP (Table 1). The latter cohort of patients were characterized by
tau pathology and neurodegeneration in the frontal cortex.
As mentioned, FTLD-TDP can be further classified on the
basis of morphology and distribution of TDP-43 inclusions. As
such, our cohort of patients with FTLD-TDP were classified into
different TDP-43 pathological subtypes: 117 patients were type A
(27 and 34 patients carried a mutation in C9orf72 or GRN, respectively), 66 were type B (21 and 1 carried a mutation in C9orf72 or
GRN, respectively), 43 were type C (2 and 1 carried a mutation in
C9orf72 or GRN, respectively), and 2 were type D (both patients
had VCP mutants) (Table 1). In addition to conducting our analyses of all FTLD-TDP cases combined, we also evaluated whether truncated STMN2 accumulation was preferentially associated
with a particular TDP-43 subtype. In the frontal cortex, we found
6084
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that truncated STMN2 RNA levels were significantly elevated in all
patients with FTLD-TDP compared with levels in the control subjects without disease or those with PSP disease in both unadjusted
analysis (P < 0.001) (Figure 4A, Table 2, and Supplemental Table
2) and analysis adjusted for age at death, sex, and RNA integrity
number (RIN) (P = 0.009 vs. controls, P < 0.001 vs. patients with
PSP) (Figure 4A, Table 2, and Supplemental Table 2). We also
noted that the levels of truncated STMN2 in individuals with PSP
were significantly lower than those in control subjects (P = 0.028,
adjusted analyses for age, sex, and RIN), possibly because of the
neuronal loss in the patients with PSP.
As in all patients with FTLD-TDP combined, truncated STMN2
RNA levels in the frontal cortex were increased in FTLD-TDP for
each TDP-43 type (A–D) compared with levels in patients with
PSP in both unadjusted and adjusted analyses (Table 2 and Sup-
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Table 1. Patient characteristics in the postmortem cohort
Variable
Age at death (yr)
Sex
Male
Female
Survival after onset (yr)
Age at onset (yr)
RIN

Controls
(n = 33)

PSP
(n = 41)

All FTLD-TDP
(n = 238)

FTLD-TDP type A
(n = 117)

FTLD-TDP type B
(n = 66)

FTLD-TDP type C
(n = 43)

FTLD-TDP type D
(n = 2)

82 (55, 99)

69 (52, 86)

72 (49, 100)

76 (50, 100)

67 (49, 98)

74 (60, 84)

63 (61, 64)

20 (60.6%)
13 (39.4%)
NA
NA
9.6 (7.1, 10.0)

13 (51.2%)
20 (48.8%)
7.0 (4.0, 14.0)
61.5 (46.0, 79.5)
9.5 (7.1, 10.0)

130 (54.6%)
108 (45.4%)
7.0 (0.6, 25.0)
64.5 (40.0, 85.8)
9.5 (7.0, 10.0)

63 (53.8%)
54 (46.2%)
7.0 (1.0, 25.0)
67.8 (40.0, 85.8)
9.4 (7.0, 10.0)

37 (56.1%)
29 (43.9%)
4.0 (0.6, 20.0)
61.4 (44.0, 85.7)
9.6 (7.0, 10.0)

23 (53.5%)
20 (46.5%)
10.6 (4.0, 25.0)
62.7 (46.0, 76.0)
9.5 (7.8, 10.0)

1 (50.0%)
1 (50.0%)
8.5 (7.0, 10.0)
54.1 (54.0, 54.2)
9.9 (9.8, 10.0)

The sample median (minimum, maximum) is given for continuous variables. Information was unavailable regarding TDP-43 subtype (all FTLD-TDP: n = 10),
age at death (all FTLD-TDP: n = 1), p–TDP-43 burden in the frontal cortex (all FTLD-TDP: n = 1), survival after onset (PSP: n = 4; all FTLD-TDP: n = 20), and age
at onset (PSP: n = 4; all FTLD-TDP: n = 20). Among the patients with FTLD-TDP, 50 had C9orf72 mutations (n = 27 TDP-43 type A, n = 21 TDP-43 type B, n = 2
TDP-43 type C), 36 had GRN mutations (n = 34 TDP-43 type A, n = 1 TDP-43 type B, n = 1 TDP-43 type C), and 2 had VCP mutations (TDP-43 type D).

plemental Table 2). Compared with controls, truncated STMN2
levels were significantly increased in patients with FTLD-TDP
types A, B, and C, but not in those with type D, in unadjusted analyses (Table 2 and Supplemental Table 2), although the levels only
in those with type A FTLD-TDP remained significant in analyses
adjusted for age, sex, and RIN (Table 2 and Supplemental Table 2).
We observed that truncated STMN2 levels in the frontal cortex
discriminated between the patients with FTLD-TDP and the PSP
control subjects, with an area under the receiver operating characteristic curve (AUC) of 0.76 (95% CI = 0.69–0.84) (Table 2). Frontal
cortex truncated STMN2 also discriminated between FTLD-TDP
patients and cognitively normal controls with a more modest AUC
of 0.67 (95% CI = 0.57–0.78) (Supplemental Table 2). Furthermore, truncated STMN2 levels similarly discriminated between
controls (cognitively normal or PSP disease controls) and patients
with FTLD-TDP of all TDP-43 types, most prominently for types
A, C, and D (Table 2 and Supplemental Table 2). In contrast, truncated STMN2 levels did not effectively distinguish patients with
PSP from control subjects (AUC: 0.60, 95% CI = 0.47–0.73).
The increase in truncated STMN2 levels in FTLD-TDP frontal cortex was paired with a decrease in full-length STMN2 levels
(P < 0.001) (Figure 4B and Supplemental Table 3). Of interest, fulllength STMN2 expression was also decreased in patients with PSP
compared with expression levels in controls (P < 0.001) (Figure
4B and Supplemental Table 3), probably because of neurodegeneration in this region. Full-length STMN2 levels also distinguished
control subjects from patients with FTLD-TDP (AUC: 0.74)
and PSP (AUC: 0.83), but were not as effective in distinguishing
patients with FTLD-TDP from those with PSP (AUC: 0.60, 95%
CI = 0.51-0.68; Supplemental Table 3).
Taken together, our data show that truncated STMN2 RNA
levels were significantly elevated in patients with FTLD-TDP
compared with levels in controls and may be used to distinguish
FTD patients with TDP-43 pathology from both cognitively normal individuals and disease controls.
Truncated STMN2 RNA associates with p–TDP-43 burden in the
frontal cortex of patients with FTLD-TDP. That truncated STMN2
levels were elevated in the frontal cortex of patients with FTLDTDP but not in those with PSP (Figure 4A) or other forms of FTLD

(FTLD-tau, FTLD-FUS) or ALS (ALS-SOD1) (Figure 3) suggests
that truncated STMN2 production is caused by a loss of TDP-43
nuclear function resulting from its mislocalization to the cytoplasm and/or its sequestration into inclusions — hallmark features
of FTLD-TDP. To evaluate this possibility further, we examined
whether full-length or truncated STMN2 RNA levels in the frontal cortex correlated with p–TDP-43 accumulation. To this end,
we prepared urea-soluble protein lysates from the same tissues
used to measure STMN2 isoforms and quantified p–TDP-43 in
these lysates using a previously described immunoassay (32–34).
Although the levels of full-length STMN2 did not associate with
p–TDP-43 levels (β: 0.02, P = 0.53) (Supplemental Table 4), higher
p–TDP-43 levels were associated with higher truncated STMN2 RN
A levels (Figure 4C) in both unadjusted analyses (β: 0.20,
P < 0.001) (Table 3) and in a multivariable analysis adjusted for
age, sex, and TDP-43 subtype (β: 0.19, P < 0.001) (Table 3). Taken together, our data suggest that truncated STMN2 RNA, but not
full-length STMN2, accumulates in brain regions marked by TDP43 pathology and associates with p–TDP-43 burden.
Truncated STMN2 RNA levels associate with an earlier age of
FTLD-TDP onset. We additionally examined whether truncated or
full-length STMN2 levels in the frontal cortex associate with clinical
characteristics of individuals with FTLD-TDP. We found a significant
inverse correlation between truncated STMN2 RNA levels and age at
disease onset (Figure 4D) in analyses, adjusting for sex, age at death,
and TDP-43 type and after correcting for multiple testing (P = 0.005)
(Table 3). However, survival after onset did not associate with truncated STMN2 RNA levels, after correcting for age at onset, sex, and
TDP-43 subtype (P = 0.32) (Table 3). Of interest, we observed a nominal but not statistically significant association with lower truncated
STMN2 levels in males (β: –0.35, P = 0.034 in adjusted analyses for
age and TDP-43 type) (Supplemental Table 4). In contrast, full-length
STMN2 levels failed to associate with clinical features of FTLD-TDP,
including age of onset and survival (Supplemental Table 4).

Discussion

FTLD, the neuropathological substrate of FTD, is the second
most common cause of early-onset dementia (35). Although no
effective treatment is available, several therapeutic approaches
jci.org   Volume 130   Number 11   November 2020
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Figure 4. Truncated STMN2 is elevated in FTLD-TDP and associates with higher p–TDP-43 burden and earlier age of FTD onset. (A and B) Truncated and fulllength STMN2 levels were measured in RNA extracted from frontal cortex of control subjects and FTLD-TDP and PSP patients, using the NanoString PlexSet
platform. (A) A significant accumulation of truncated STMN2 RNA was detected in patients with FTLD-TDP but not in controls (see also Supplemental Table 2)
or patients with PSP (see also Table 2). (B) Full-length STMN2 levels were significantly decreased in FTLD-TDP and PSP patients (see also Supplemental Table
3). Data are presented as the median with a 95% CI, and P values were determined using linear regression models that were adjusted for age at death, sex,
and RIN. *P < 0.05, ***P < 0.005, ****P < 0.001. (C and D) In our FTLD-TDP cohort (n = 238), significant correlations were observed between truncated STMN2
RNA levels and (C) a higher burden of p–TDP-43 and (D) an earlier age of disease onset. See Table 3 for the correlation coefficients.

are being investigated to target TDP-43 and tau, the 2 proteins
most commonly associated with the major pathological FTLD
subtypes. Their testing in clinical trials, however, faces a considerable barrier: our inability to determine the underlying protein
pathology in living patients with FTD. Although the pathomechanisms driven by TDP-43 and tau differ, the clinical symptoms of
FTD patients with TDP-43 or tau pathology overlap. Ultimately,
this hinders the selection of patients with sporadic FTD who are
suitable for a particular clinical trial. Since there is a clear need
for biomarkers to identify FTD patients with TDP-43 pathology,
we evaluated whether truncated STMN2 could serve as a proxy
for TDP-43 pathology. Using RNA-Seq and RNA quantification
techniques, we show that truncated STMN2 RNA levels were
elevated in human iPSC–derived neurons depleted of TDP-43
and in bulk tissue from FTD and ALS patients with TDP-43
pathology. We did not detect truncated STMN2 in iPSC-derived
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neurons with pathogenic TARDBP mutations where no change
in TDP-43 levels, localization, or aggregates was detected, supporting the fact that loss of TDP-43 nuclear function, and not
splicing changes induced by pathogenic mutations, were driving this event. We were unable to assess postmortem tissue
from patients carrying TARDBP mutations, which are rare in
the FTD and ALS populations, as a group, but given that these
patients develop florid TDP-43 pathology, we expected truncated STMN2 to be present at levels similar to those in patients
with sporadic ALS or FTLD-TDP. Additionally, we found that
truncated STMN2 RNA accumulated in the frontal cortex of
patients with FTLD-TDP but not in control subjects or patients
with PSP and was significantly correlated with p–TDP-43 levels
and an earlier age of disease onset. Taken together, our data
support the notion that truncated STMN2 production results
from TDP-43 loss of function.
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Table 2. Comparisons of truncated STMN2 RNA in frontal cortex between patients with FTLD-TDP and patients with PSP.
Unadjusted analysis
Group
PSP
All FTLD-TDP
FTLD-TDP type A
FTLD-TDP type B
FTLD-TDP type C
FTLD-TDP type D

Adjusting for age at death, sex, and RIN

n

Median (minimum, maximum)
levels of truncated STMN2 RNA

Regression coefficient
(95% CI)

P value

Regression coefficient

P value

AUC (95% CI)
vs. PSP cases

41
238
117
66
43
2

217 (22, 880)
560 (8, 5210)
595 (8, 3495)
494 (62, 5210)
575 (106, 2071)
1035 (1008, 1062)

0.00 (reference)
1.38 (0.96, 1.80)
1.47 (0.98, 1.95)
1.28 (0.77, 1.79)
1.34 (0.79, 1.89)
2.40 (0.25, 4.55)

NA
< 0.001
< 0.001
< 0.001
< 0.001
0.029

0.00 (reference)
1.36 (0.95, 1.77)
1.37 (0.87, 1.86)
1.29 (0.79, 1.78)
1.26 (0.73, 1.78)
3.07 (1.07, 5.07)

NA
< 0.001
< 0.001
< 0.001
< 0.001
0.004

NA
0.76 (0.69, 0.84)
0.78 (0.70, 0.86)
0.74 (0.65, 0.84)
0.77 (0.66, 0.87)
1.00 (1.00, 1.00)

(95% CI)

Regression coefficients, 95% CIs, and P values were determined using linear regression models, where the levels of truncated STMN2 RNA in the frontal
cortex were considered on the base 2 logarithmic scale. Regression coefficients were interpreted as the difference in mean levels of truncated STMN2 RNA
in the frontal cortex (on the base 2 logarithmic scale) between the given group of patients with disease and patients with PSP. P values of 0.010 or less
were considered statistically significant after applying a Bonferroni’s correction for multiple testing.

As mentioned above, 2 independent reports recently revealed
that TDP-43 regulates STMN2 expression and that TDP-43 depletion produces a truncated, nonfunctional STMN2 variant (7, 8).
Increased truncated STMN2 RNA levels were detected in spinal
cord tissue of 17 patients with ALS but not in that of 6 controls, and
ISH studies found truncated STMN2 RNA in lower and upper motor
neurons in 5 patients with ALS (8). We thus evaluated truncated
STMN2 as a proxy TDP-43 activity marker for FTD using postmortem RNA-Seq data across 11 tissues available from a large cohort
of FTD, ALS, and FTLD-ALS patients. Notably, our RNA-Seq analyses detected the STMN2 cryptic exon that gives rise to truncated
STMN2 only in FTD and ALS patients with TDP-43 pathology. In
addition, the presence of abnormal STMN2 was highly specific to
brain regions characterized by TDP-43 pathology.
In addition to our analyses of RNA-Seq data, we directly
measured truncated STMN2 RNA in postmortem frontal cortex
tissue from patients with FTLD-TDP, which again revealed an
aberrant accumulation of truncated STMN2 in comparison with
controls and individuals with PSP. In fact, we found that truncated
STMN2 RNA levels distinguished between patients with FTLDTDP and those with PSP, with an area under the ROC curve of
0.76. As anticipated, truncated STMN2 accumulation in patients
with FTLD-TDP was accompanied by a decrease in full-length
STMN2, as was observed in cell culture models (7, 8). Full-length
STMN2 was also decreased in patients with PSP, which were confirmed to lack TDP-43 pathology. Given that STMN2 is expressed
by neurons and its expression is abundant in the frontal cortex, the
decrease in full-length STMN2 in patients with PSP likely reflects
neurodegenerative neuronal loss. Indeed, a recent report found
that full-length STMN2 RNA levels were also decreased in the
brains of patients with Parkinson’s disease (36), possibly arguing
for the use of STMN2 levels as a neurodegenerative disease biomarker. It is also possible that, aside from TDP-43, various other
factors regulate full-length STMN2 expression. This could explain
why full-length STMN2 levels did not correlate with p–TDP-43
burden or with clinical features.
The accumulation of truncated STMN2 RNA in the frontal
cortex of patients with FTLD-TDP but not of patients with PSP
indicates that truncated STMN2 production is caused by patho-

logical changes in TDP-43. In line with this, we observed a significant association of truncated STMN2 RNA with p–TDP-43
protein levels (P < 0.001, Table 3), which remained statistically significant after controlling for multiple variables (age, sex,
and TDP-43 subtype; P < 0.001, Table 3). However, it is possible
that p–TDP-43 levels alone may not be a perfect corollary for
nuclear TDP-43 depletion. Of interest, the levels of truncated
STMN2 RNA did not differ among different TDP-43 subtypes,
suggesting that truncated STMN2 levels are elevated in all types
of TDP-43 pathology.
Importantly, higher truncated STMN2 RNA levels in the frontal cortex at death were significantly associated with an earlier age
at disease onset (P = 0.005, Table 3), but we found no association
with survival after disease onset. Given that truncated STMN2
RNA serves as a proxy for TDP-43 dysfunction, this earlier age
of onset in patients with higher postmortem truncated STMN2
RNA levels could point to more severe defects in RNA metabolism resulting from aberrant TDP-43 function, including loss of
STMN2 function.
Strengths of our study include the use of samples from a clinically well-characterized, immunohistologically confirmed cohort
of 238 patients with FTLD-TDP from which high-integrity RNA
was extracted from the frontal cortex, and the use of quantitative
measurements of truncated STMN2 RNA and p–TDP-43 protein.
Moreover, we evaluated multiple neuroanatomical regions in bulk
tissue RNA-Seq from a large data set that included 1659 FTD and
ALS patients with and without TDP-43 pathology. Further, our
study also used 3 different approaches (RNA-Seq, NanoString,
and qRT-PCR, the latter of which was also performed to validate
truncated STMN2 in patients with FTLD-TDP, as shown in Supplemental Figure 9) that have different sensitivity and specificity
linked to the methodology but that all detect significant differences in truncated STMN2, highlighting the reproducibility of the
finding. Our study also has some limitations. While we specifically
designed our study to evaluate truncated STMN2 as a marker of
TDP-43 pathology — information important to establish its value
as a candidate biomarker — we did not measure the translation
product from this truncated variant because of a lack of commercially available antibodies. At present, it is unclear whether
jci.org   Volume 130   Number 11   November 2020
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Table 3. Associations of truncated STMN2 with p–TDP-43 and clinical characteristics in FTLD-TDP frontal cortex
Association with frontal cortex truncated STMN2 RNA
Unadjusted analysis
Variable

P value

Multivariable model adjustments

0.20 (0.12, 0.28)
< 0.001
Overall test of difference: P = 0.48
0.00 (reference)
NA
–0.19 (–0.57, 0.19)
0.33
–0.13 (–0.56, 0.31)
0.57
0.93 (–0.91, 2.77)
0.32
–0.23 (–0.41, –0.04)
0.015
0.12 (–0.06, 0.30)
0.19

0.19 (0.09, 0.28)
< 0.001
Overall test of difference: P = 0.33
0.00 (reference)
NA
–0.31 (–0.72, 0.10)
0.14
–0.16 (–0.60, 0.27)
0.46
0.68 (–1.17, 2.53)
0.47
–0.29 (–0.49, –0.09)
0.005
0.10 (–0.09, 0.29)
0.32

Age at death, sex, TDP-43 subtype
Age at death and sex

–0.37 (–0.68, –0.06)
0.00 (reference)

–0.35 (–0.67, –0.03)
0.00 (reference)

Regression coefficient
(95% CI)

p–TDP-43 (doubling)
TDP-43 subtype
FTLD-TDP type A
FTLD-TDP type B
FTLD-TDP type C
FTLD-TDP type D
Age at onset (10-yr increase)
Survival after onset (5-yr increase)
Sex
Male
Female

Multivariable analysis
P value

0.019
NA

Regression coefficient
(95% CI)

0.034
NA

Sex and TDP-43 subtype
Age at onset, sex, and TDP-43 subtype
Age at death and TDP-43 subtype

Regression coefficients, 95% CIs, and P values were determined using linear regression models, where frontal cortex truncated STMN2 RNA was
considered on the base 2 logarithmic scale. Regression coefficients were interpreted as the change in mean frontal cortex truncated STMN2 RNA (on
the base 2 logarithmic scale) corresponding to the presence of the indicated characteristic (categorical variables) or the increase shown in parentheses
(continuous variables). P values of 0.010 or less were considered statistically significant after applying a Bonferroni’s correction for multiple testing.

the predicted peptide of only 16 amino acids is translated from
truncated STMN2 RNA. Nevertheless, our findings indicate that
the development of novel tools (antibodies, immunoassays) for
the detection of truncated STMN2 protein and additional studies to evaluate the role of truncated STMN2 RNA and protein in
disease pathogenesis and as biomarkers are well merited. Critical next steps to hasten the translation of this finding to the clinic
include determining whether truncated STMN2 RNA or protein
is detected in the biofluids of patients with FTD (e.g., spinal fluid and blood) and, if so, whether they discriminate between FTD
subtypes (i.e., with or without TDP-43). Although expression of
truncated STMN2 in affected postmortem tissues can distinguish
FTLD-TDP from PSP cases, which has important implications, as
it supports truncated STMN2 as a viable proxy for the presence of
TDP-43 pathology, the ability to discriminate between FTLD-TDP
and PSP patients was only modest (AUC: 0.76). RNA degradation
invariably occurs in postmortem brain tissues, possibly contributing to this modest AUC and potentially pointing toward the
possibility of detecting truncated STMN2 in CSF or blood, which
are typically frozen immediately after collection, to discriminate
between patient groups. Nonetheless, sensitive methods will be
needed to detect truncated STMN2 RNA and/or protein in human
biofluids. Additionally, determining at what point during the
course of disease truncated STMN2 levels begin to be upregulated will have to be evaluated and will probably require longitudinal
collections of CSF and blood first from patients with ALS, who are
almost certain to develop TDP-43 pathology, and then from individuals with FTD or FTD/ALS harboring genetic variants associated with TDP-43 dysfunction.
If, as anticipated, truncated STMN2 RNA or protein is detected in the biofluids of FTD patients with TDP-43 pathology, it may
have the potential to similarly identify those patients with AD
who have TDP-43 pathology. Indeed, up to 67% of patients with
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AD develop TDP-43 inclusions, and, compared with AD patients
without TDP-43 pathology, they are cognitively and functionally
worse, suggesting that abnormal TDP-43 causes a modified AD
phenotype (37–46). Our work also highlights how future means to
detect truncated STMN2 RNA or protein in biofluids may provide
important information on disease activity and therefore be useful
in assessing drug efficacy in clinical trials. Thus, these endeavors
are expected to increase the likelihood of success in developing
effective therapeutics and improving the care of patients with
TDP-43 proteinopathies.

Methods

RNA extraction, complementary DNA synthesis, and qRT-PCR in iPSC-derived neurons. iPSC-derived neurons were harvested, and cell pellets were
lysed in TRI reagent (Zymo Research). Then, total RNA was extracted following the manufacturer’s instructions using the Direct-zol RNA Miniprep
Kit (Zymo Research), and 850 ng RNA was used for RT-PCR. RT-PCR of
RNA samples was performed using the High Capacity cDNA Transcription Kit with random primers (Applied Biosystems), and qRT-PCR was
performed using SYBR GreenER qPCR SuperMix (Invitrogen, Thermo
Fisher Scientific). Samples were run in triplicate, and qRT-PCRs were run
on a Prism 7900HT Fast Real-Time system (Applied Biosystems). Relative
quantification was determined using the ΔΔCt method and normalized to
the endogenous controls RPLP0 and GAPDH. The following primers and
their sequences were used: STMN2 forward: 5′-AGCTGTCCATGCTGTCACTG-3′, STMN2 reverse: 5′-GGTGGCTTCAAGATCAGCTC-3′;
truncated STMN2 forward: 5′-GGACTCGGCAGAAGACCTTC-3′, truncated STMN2 reverse: 5′-GCAGGCTGTCTGTCTCTCTC-3′; TARDBP
forward: 5′-AATTCTGCATGCCCCAGA-3′, TARDBP reverse: 5′-GAAGCATCTGTCTCATCCATTTT-3′; GAPDH forward: 5′-GTTCGACAGTCAGCCGCATC-3′, GAPDH reverse: 5′-GGAATTTGCCATGGGTGGA-3′; and RPLP0 forward: 5′-TCTACAACCCTGAAGTGCTTGAT-3′,
RPLP0 reverse: 5′-CAATCTGCAGACAGACACTGG-3′.
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RNA-Seq analyses from iPSC-derived neurons. Data from Klim et
al. (7) were downloaded from the NCBI’s Gene Expression Omnibus
(GEO) database (GEO GSE121569). All iPSC cells lines were analyzed
with the same analysis pipeline. Raw FASTQ files were trimmed using
fastp (47) and aligned to the hg38 build (GRCh38.primary_assembly)
of the human reference genome using STAR (2.7.2a) (48). Gene abundance for TARDBP and STMN2 was calculated with featureCounts (49)
using gene models from GENCODE GTF, version 31, and converted to
reads per kilobase per million (RPKM) using edgeR (50). The relative
abundance of truncated STMN2 as a proportion of total STMN2 was
expressed in terms of percent spliced in (PSI) (51). This was calculated
by parsing the splice junction tables from STAR and taken as the percentage of all uniquely mapped STMN2 junction reads from exon 1 to
exon 2a over the sum of all junction reads coming from exon 1.
NYGC ALS Consortium cohort. Patients with FTD were classified according to a pathologist’s diagnosis of FTD with TDP-43
inclusions (FTLD-TDP), tau inclusions (FTLD-tau), or FUS inclusions (FTLD-FUS). ALS samples were divided into the following
subcategories using the available Consortium metadata: ALS with
or without reported SOD1 mutations (ALS-TDP and ALS-SOD1);
ALS with frontotemporal dementia (ALS-FTLD); and ALS with
AD (ALS-AD). All non-SOD1 ALS samples were grouped as “ALSTDP” in this work for simplicity, although reporting of postmortem
TDP-43 inclusions was not systematic and therefore not integrated
into the metadata. Confirmed TDP-43 pathology postmortem was
reported for all FTLD-TDP samples.
NYGC ALS Consortium RNA-Seq library preparation from bulk tissue RNA. The Consortium’s sample processing has been, in part, previously described (52). In brief, RNA was extracted from flash-frozen
postmortem tissue using TRIzol (Thermo Fisher Scientific) chloroform, followed by column purification (RNeasy Minikit, QIAGEN).
RIN was assessed on a Bioanalyzer (Agilent Technologies). RNASeq libraries were prepared from 500 ng total RNA using the KAPA
Stranded RNA-Seq Kit with RiboErase (KAPA Biosystems) for rRNA
depletion and Illumina-compatible indexes (NEXTflex RNA-Seq Barcodes, NOVA-512915, PerkinElmer, and IDT for Illumina TruSeq UD
Indexes, 20022370). Pooled libraries (average insert size: 375 bp)
passing the quality criteria were sequenced either on an Illumina HiSeq 2500 (125 bp paired end) or an Illumina NovaSeq (100 bp paired
end). Samples were subjected to extensive sequencing and RNA-Seq
quality control metrics at the NYGC that are described below. Notably, a set of more than 250 markers was used to confirm tissue, neuroanatomical regions, and sex in the RNA-Seq data. Samples passing
these metrics are available for distribution. The samples had a median
sequencing depth of 42 million read pairs, with a range between 16
and 167 million read pairs.
Analyses of bulk tissue RNA-Seq data. Samples were uniformly
processed using RAPiD-nf, an efficient RNA-Seq processing pipeline
implemented in the NextFlow framework (53). Following adapter
trimming with Trimmomatic (version 0.36) (54), all samples were
aligned to the hg38 build (GRCh38.primary_assembly) of the human
reference genome using STAR (2.7.2a) (48), with indexes created from
GENCODE, version 30 (55). Gene expression was quantified using
RSEM (1.3.1) (56). Quality control was performed using SAMtools (57)
and Picard Tools (58), and the results were collated using MultiQC
(59). Exploratory plots were created in R, version 3.6.0 (60), using
dplyr, tidyr, stringr, ggplot2, patchwork, and ggpubr packages (61–63).
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RNA-Seq samples were subjected to quality control modeled on
the criteria of the Genotype Tissue Expression Consortium (64). Any
sample failing 1 of the following sequencing metric thresholds was
removed: a unique alignment rate of less than 90%, ribosomal bases
of greater than 10%, a mismatch rate of greater than 1%, a duplication rate of greater than 0.5%, intergenic bases of less than 10.5%, and
ribosomal bases of greater than 0.1%. Sex was verified using XIST and
UTY expression. Tissue identity was confirmed using the expression
of the cerebellar marker CBNL1 and the cortical marker NRGN. Spinal
cord samples were confirmed by expression of the oligodendrocyte
marker MBOP. Following quality control, 1905 samples of 1924 were
retained for analysis. When comparing subgroups and tissues, only
tissues with at least 50 samples and disease subgroups with at least 4
individuals were kept for analysis. This resulted in 1659 samples from
11 tissues and 439 donors.
Expression of the full-length STMN2 isoform was estimated
using RSEM, summing the estimates of the 3 annotated isoforms
in GENCODE, version 30, into a gene-level estimate of expression
normalized in terms of TPM. Given the large size of the NYGC ALS
cohort, RNA-Seq data were produced on 2 different sequencing platforms. Exploratory analyses showed a substantial batch effect in gene
expression due to the 2 sequencing platforms. We therefore split the
data set by sequencing platform, along with tissue and disease status.
A comparison of ALS-TDP and non-neurological controls revealed
that STMN2 had an inconsistent pattern of differential expression,
with no tissue showing a marked difference in either platform (Supplemental Figure 4A). In addition, RNA degradation is known to
affect the estimation of transcript abundance (65, 66), and we reasoned that systematic differences in RNA quality among samples
sequenced on different platforms and between disease and control
groups or tissues could confound our estimation of STMN2 expression. We compared the RIN values for each sample between the ALSTDP and control groups and found significant differences in RIN
values in some comparisons (Supplemental Figure 4B). The small
number of controls available limited further comparisons in some tissues. We then correlated the RIN with STMN2 expression and found
a positive correlation in multiple tissues and on both sequencing platforms (Supplemental Figure 4C).
Quantifying STMN2 splicing from RNA-Seq data. For downstream
analysis of STMN2 splice junction reads, a bioinformatics pipeline was
created using Snakemake (67, 68). Uniquely mapped reads within the
STMN2 locus were extracted from each sample using SAMtools. Any
read marked as a PCR duplicate by Picard Tools was discarded. Splice
junction reads were then extracted with RegTools (69) using a minimum of 8 bp as an anchor on each side of the junction and a maximum
intron size of 500 kb. Junctions from each sample were then clustered
together using LeafCutter (70) with relaxed junction filtering (minimum
total reads per junction = 30, minimum fraction of total cluster reads =
0.0001). This produced a matrix of junction counts across all samples.
Using coordinates from the Klim (7) and Melamed (8) publications, the
TDP-43–associated junction of the novel truncated STMN2 isoform was
extracted from the matrix. A detection threshold of 2 or more uniquely mapped reads was applied. We found no association between truncated STMN2 detection and RIN, sequencing platform, or total library
size (Supplemental Figure 8, A–C). The relationship between expression
levels of full-length and truncated STMN2 was complex, with no overall
detection of association across tissues (Supplemental Figure 8D).
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RNA extraction and NanoString analyses in postmortem tissues.
Using the RNAeasy Plus Mini Kit (QIAGEN), RNA was extracted
from frozen human postmortem frontal cortex tissues (33). RNA
with a RIN of 7.0 or higher, as determined using an Agilent 2100
bioanalyzer (Agilent Technologies), was used to measure transcript
levels using the NanoString PlexSet platform (250 ng human brain
RNA, according to the manufacturer’s instructions). Transcript level abundance was determined using nSolver 4.0 software (Nano
String Technologies) and normalized to HTRP1, a housekeeping
gene that was unaltered across disease subtypes in our data set
and previously used to normalize human brain transcripts (71). The
sequences of the NanoString probes used in this study are included
in Supplemental Table 5.
p–TDP-43 immunoassay. The p–TDP-43 immunoassay was performed as previously described (33). Briefly, approximately 50 mg
postmortem tissue from the frontal cortex of patients or unaffected individuals were homogenized in cold RIPA buffer (25 mM TrisHCl, pH 7.6, 150 mM NaCl, 1% sodium deoxycholate, 1% Nonidet
P-40, 0.1% sodium dodecyl sulfate, and protease and phosphatase
inhibitors) and sonicated on ice. Homogenates were centrifuged at
100,000g for 30 minutes at 4°C. The supernatant was collected, and
the pellet was resuspended in RIPA buffer, sonicated and centrifuged
again to prevent carryover of soluble material. The RIPA-insoluble
pellet was extracted using 7 M urea buffer and then sonicated and
centrifuged at 100,000g for 30 minutes at 22°C. The protein concentration of the urea-soluble supernatant was determined by Bradford
assay. p–TDP-43 levels were determined using a sandwich Meso Scale
Discovery (MSD) immunoassay. The capture antibody was a mouse
monoclonal antibody that detects TDP-43 phosphorylated at serines
409/410 (1:500, no. CAC-TIP-PTD-M01, Cosmo Bio USA), and the
detection antibody was a sulfo-tagged rabbit polyclonal C-terminal
TDP-43 antibody (2 μg/mL, 12892-1-AP, Proteintech). Urea-soluble fractions were diluted in TBS to 35 μg protein per well and tested in duplicate wells. Response values corresponding to the intensity
of emitted light upon electrochemical stimulation of the assay plate
using the MSD QUICKPLEX SQ120 were acquired.
Statistics. Comparisons of truncated STMN2 RNA in the frontal
cortex between the separate non–FTLD-TDP groups of controls and
patients with PSP and various groups of patients with FTLD-TDP
(all FTLD-TDP patients as well as 4 different subgroups according
to the TDP-43 subtype) were made using single-variable (i.e., unadjusted) and multivariable linear regression models. Multivariable
models were adjusted for age at death, sex, and RIN, and truncated
STMN2 RNA in the frontal cortex was examined on the base 2 logarithmic scale, owing to its skewed distribution. Regression coefficients (referred to as β) and 95% CIs were estimated and interpreted
as the difference in mean truncated STMN2 RNA levels in the frontal
cortex (on the base 2 logarithmic scale) between the given group of
FTLD-TDP patients and the given reference group (cognitively normal controls or patients with PSP). Additionally, to further assess the
ability of truncated STMN2 RNA in the frontal cortex to discriminate
between FTLD-TDP and non–FTLD-TDP individuals (again, separately for cognitively normal controls and patients with PSP), we
estimated the area under the ROC curve (AUC); an AUC of 0.5 corresponded to the predictive ability equal to that of chance, whereas an
AUC of 1.0 indicated perfect predictive ability. Bonferroni’s correction was applied to adjust for the 5 different statistical tests that were
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performed for the separate FTLD-TDP versus control and FTLDTDP versus PSP analyses, after which P values of less than 0.01 were
considered statistically significant.
In a secondary analysis, we compared truncated STMN2 RNA levels between controls and patients with PSP and made pairwise comparisons of full-length STMN2 RNA and p–TDP-43 (both on the base
2 logarithmic scale) between controls, patients with PSP, and patients
with FTLD-TDP using the aforementioned linear regression analyses.
In the subgroup of 238 patients with disease, associations of 5 different variables (p–TDP-43 levels, TDP-43 subtype, age at onset, survival after onset, and sex) with both truncated and full-length STMN2
RNA levels were evaluated using single-variable and multivariable linear regression models, where truncated and full-length STMN2 RNA
levels in the frontal cortex were assessed on the base 2 logarithmic
scale, and multivariable models were adjusted for predefined, potentially confounding variables. The multivariable model assessing the
p–TDP-43 response in frontal cortex was adjusted for age at death, sex,
and TDP-43 subtype. The multivariable model assessing TDP-43 subtype was adjusted for sex and age at death. The multivariable model
assessing age at onset was adjusted for sex and TDP-43 subtype. The
multivariable model assessing survival after onset was adjusted for
age at onset, sex, and TDP-43 subtype. Finally, the multivariable model assessing sex was adjusted for age at death, TDP-43 subtype, and
genotype. Regression coefficients and 95% CIs were estimated and
are interpreted as the change in the mean level of truncated or fulllength STMN2 RNA in the frontal cortex (on the base 2 logarithmic
scale) corresponding to the presence of the given characteristic (categorical variables) or a specified increase (continuous variables). The
p–TDP-43 response in the frontal cortex was examined on the base 2
logarithmic scale in linear regression analysis because of its skewed
distribution. In order to adjust for the 5 different variables that were
assessed for association with the separate truncated and full-length
STMN2 RNA outcomes, we used Bonferroni’s correction for multiple
testing, after which P values of less than 0.01 were considered statistically significant. All statistical tests were 2 sided. All statistical analyses described above were performed using R Statistical Software,
version 3.6.2 (R Foundation for Statistical Computing).
Statistical analyses for iPSC studies and qRT-PCR of RNA extracted from human tissues were performed using GraphPad Prism 8
(GraphPad Software), in which 1-way ANOVA with Bonferroni’s
post hoc test was performed for multiple group comparisons, and an
unpaired Student t test was performed when only 2 groups were compared. The statistical test and number of independent experiments
used for each analysis are indicated in the figure legends.
Study approval. The NYGC ALS Consortium samples presented in
this work were acquired through various IRB protocols from member
sites and the Target ALS postmortem tissue core and transferred to the
NYGC in accordance with all applicable foreign, domestic, federal, state,
and local laws and regulations for processing, sequencing, and analyses.
Postmortem brain tissues from patients with FTLD-TDP or PSP
and from cognitively normal individuals were obtained from the Mayo
Clinic Florida Brain Bank. Diagnosis was independently ascertained
by trained neurologists and neuropathologists upon neurological and
pathological examinations, respectively. Written informed consent
was given by all participants or authorized family members, and all
protocols were approved by the IRB and ethics committee of the Mayo
Clinic. A summary of the patients’ characteristics is provided in Table 1.
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Sample size was determined by tissue availability and the quality of
RNA obtained from such samples, as described below.
Data and code availability. RNA-Seq data generated through the
NYGC ALS Consortium in this study can be accessed via the NCBI’s
GEO database (GEO GSE137810, GSE124439, GSE116622, and
GSE153960). All RNA-Seq data generated by the NYGC ALS Consortium are made immediately available to all members of the Consortium and with other consortia with whom we have a reciprocal sharing
arrangement. To request immediate access to new and ongoing data
generated by the NYGC ALS Consortium and for samples provided
through the Target ALS Postmortem Core, complete a genetic data
request form at ALSData@nygenome.org.
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